Mufemilast vs PALI-2108

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: PDE4 · full Ulcerative Colitis pipeline

Mufemilast

Marketed by Tianjin Hemay Pharmaceutical

Phase 3 in Ulcerative Colitissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT05486104 (registry estimate)

No aligned efficacy figure on record for this race.

PALI-2108

Developed by Palisade Bio

Phase 2 in Ulcerative ColitisSmall molecule (colon-targeted PDE4 inhibitor prodrug)
Weak signal

NCT06663605 · Phase 1 · completed

Most of this study randomized healthy volunteers to PALI-2108 or matching placebo under double-blind conditions, though the ulcerative colitis patient cohort was open-label. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Incidence of Treatment-Emergent Adverse Events (TEAE) or abnormal clinical laboratory measure, electrocardiogram (ECG), or vital sign. [ Safety and Tolerability ]". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: October 2027 · NCT07845487 (registry estimate)

Reported efficacy

Incidence of Treatment-Emergent Adverse Events (TEAE) or abnormal clinical laboratory measure, electrocardiogram (ECG), or vital sign. [ Safety and Tolerability ] (SAD and FE Phase: [ Day 1 to Day 7 ], MAD and UC Phase: [ Days 1 to Day 28 ]): Phase 1a: the study met its primary endpoints of safety, tolerability and pharmacokinetics, with no serious adverse events and no treatment-emergent adverse events related to laboratory values or EKGs across the single and multiple ascending dose cohorts. In the single-dose study (15 to 450 mg) only mild, reversible treatment-emergent adverse events occurred, limited to the 450 mg dose. Multiple-dose cohorts (15, 30 and 50 mg twice daily over 7 days, and 30 mg titrated over 7 days) showed mostly minor events, with one moderate event at 50 mg twice daily leading to withdrawal. (not_applicable)

Result source: NCT06663605

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMufemilastPALI-2108
Clinical remission (induction)—Trial running · NCT07650942—Not reported
Clinical remission (maintenance)—Trial running · NCT07650942—Not reported
Clinical response (induction)—Trial running · NCT07650942—Not reported
Endoscopic improvement (induction)—Trial running · NCT07650942—Not reported
Corticosteroid-free remission (maintenance)—Trial running · NCT07650942—Not reported

Clinical remission (induction)

Mufemilast
—Trial running · NCT07650942
PALI-2108
—Not reported

Clinical remission (maintenance)

Mufemilast
—Trial running · NCT07650942
PALI-2108
—Not reported

Clinical response (induction)

Mufemilast
—Trial running · NCT07650942
PALI-2108
—Not reported

Endoscopic improvement (induction)

Mufemilast
—Trial running · NCT07650942
PALI-2108
—Not reported

Corticosteroid-free remission (maintenance)

Mufemilast
—Trial running · NCT07650942
PALI-2108
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Mufemilast: no structured comparison results are available for Ulcerative Colitis.

PALI-2108: no structured comparison results are available for Ulcerative Colitis.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mufemilast's landscape · PALI-2108's landscape